Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsViva Health levoleucovorin IV Coverage Prior Auth …
    Ask Trek AI about this page
    CurrentViva HealthPolicy IC-0183

    Levoleucovorin (Fusilev; Khapzory) — Intravenous Coverage Criteria

    Customize your policy alerts

    Sign up for Viva Health Policy IC-0183 alerts

    Get alerted when Policy IC-0183 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization, dosing limits, indications, and renewal criteria for intravenous levoleucovorin (Fusilev and Khapzory) for Viva Health members.

    Policy Summary
    PayerViva Health
    PolicyLevoleucovorin (Fusilev; Khapzory) — Intravenous Coverage Criteria
    Policy CodePolicy IC-0183
    Change TypeNo material change
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization (initial approval 90 days; renew every 90 days) and confirm member is at least 6 years old.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    90 daysInitial PA duration
    J0641,J0642HCPCS codes
    2500–3000Max units/28d
    6 yrsMin member age
    dozens

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ICD-10 codes listed

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following are met:

    Universal requirements: Member is at least 6 years of age; member does not have pernicious anemia or vitamin B12 deficiency megaloblastic anemia; racemic d,l-leucovorin calcium is not obtainable in any dosage strength as confirmed by the FDA Drug Shortage website; for Khapzory only: member had an inadequate response to, or has a contraindication or intolerance to, Fusilev (levoleucovorin).

    From Universal Criteria

    Indication group: high-dose methotrexate/rescue: Member is undergoing high-dose methotrexate chemotherapy treatment OR levoleucovorin is used as rescue therapy in combination with a chemotherapy regimen containing high-dose methotrexate.

    Includes listed malignancies (e.g., osteosarcoma, ALL, CNS lymphoma, various B- and T-cell lymphomas)

    Indication: reduction of toxicity for impaired elimination/overdose: Member is undergoing treatment with a folic acid antagonist (e.g., methotrexate) AND has developed toxicity due to impaired elimination or inadvertent overdosage of the folic acid antagonist.

    Rescue for methotrexate toxicity

    Indication: combination with fluorouracil-based regimens: Levoleucovorin is used in combination with fluorouracil-based regimens for colorectal cancer and other listed tumor types; must be used with a fluorouracil-based regimen.

    See policy list of tumor types for covered diagnoses

    Indication: gestational trophoblastic neoplasia: Levoleucovorin is used in combination with a methotrexate-based regimen for gestational trophoblastic neoplasia.

    Compendia-recommended indication

    The policy includes a universal exclusion for members with pernicious anemia or vitamin B12 deficiency megaloblastic anemia. This condition is a contraindication to coverage and must be absent for authorization to be approved under the universal criteria.

    Medicare-specific coverage determinations may apply: providers must follow applicable CMS guidance, including the Medicare Benefit Policy Manual and any relevant National Coverage Determinations (NCDs) or Local Coverage Determinations (LCDs). The policy notes that Medicare Part B Covered Diagnosis Codes: N/A in Appendix 2, indicating no specific Part B diagnosis codes are listed in this document but that compliance with NCDs/LCDs is required where applicable.

    Use of levoleucovorin when racemic d,l‑leucovorin calcium is available does not meet the policy's universal criterion. Coverage requires that racemic d,l‑leucovorin calcium is not obtainable in any dosage strength as confirmed by the FDA Drug Shortage website (http://www.accessdata.fda.gov/scripts/drugshortages/default.cfm). For Khapzory specifically, this product‑substitution prerequisite is combined with the Khapzory-only requirement that the member had an inadequate response to, or intolerance/contraindication to, Fusilev.

    Billing and Coding

    HCPCS CodesHCPCSCovered
    J0641Injection, levoleucovorin, not otherwise specified, 0.5 mg; 1 billable unit = 0.5 mg (Fusilev)
    J0642Injection, levoleucovorin (khapzory), 0.5 mg; 1 billable unit = 0.5 mg
    NDCsNDC
    72893-0009-xxFusilev 50 mg single-dose vial powder for injection: 72893-0009-xx
    72893-0013-xxFusilev 175 mg/17.5 mL single-dose vial solution for injection: 72893-0013-xx
    72893-0014-xxFusilev 250 mg/25 mL single-dose vial solution for injection: 72893-0014-xx
    72893-0004-xxKhapzory 175 mg single-dose vial powder for injection: 72893-0004-xx
    72893-0006-xxKhapzory 300 mg single-dose vial powder for injection: 72893-0006-xx
    NDCsNDC
    72893-0009-xxFusilev 50 mg single-dose vial powder for injection: 72893-0009-xx
    72893-0013-xxFusilev 175 mg/17.5 mL single-dose vial solution for injection: 72893-0013-xx
    72893-0014-xxFusilev 250 mg/25 mL single-dose vial solution for injection: 72893-0014-xx
    72893-0004-xxKhapzory 175 mg single-dose vial powder for injection: 72893-0004-xx
    72893-0006-xxKhapzory 300 mg single-dose vial powder for injection: 72893-0006-xx
    Covered ICD-10 Codes (partial list from Appendix 1)ICD-10Covered
    C15.3Malignant neoplasm of upper third of esophagus
    C15.4Malignant neoplasm of middle third of esophagus
    C15.5Malignant neoplasm of the lower third of esophagus
    Covered ICD-10 Codes (partial list)ICD-10Covered
    C15.3Malignant neoplasm of upper third of esophagus
    C15.4Malignant neoplasm of middle third of esophagus
    C15.5Malignant neoplasm of the lower third of esophagus
    C15.8Malignant neoplasm of overlapping sites of esophagus
    C15.9Malignant neoplasm of esophagus, unspecified
    C16.0Malignant neoplasm of cardia
    C16.1Malignant neoplasm of fundus of stomach
    C16.2Malignant neoplasm of body of stomach
    C16.3Malignant neoplasm of pyloric antrum
    C16.4Malignant neoplasm of pylorus
    1–10 of 26
    1/3
    Covered ICD-10 Codes (continued)ICD-10Covered
    C18.6Malignant neoplasm of descending colon
    C18.7Malignant neoplasm of sigmoid colon
    C18.8Malignant neoplasm of overlapping sites of colon
    C18.9Malignant neoplasm of colon, unspecified
    C19Malignant neoplasm of rectosigmoid junction
    C20Malignant neoplasm of rectum
    C21.0Malignant neoplasm of anus, unspecified
    C21.1Malignant neoplasm of anal canal
    C21.2Malignant neoplasm of cloacogenic zone
    C21.8Malignant neoplasm of overlapping sites of rectum, anus and anal canal
    1–10 of 52
    1/6
    Covered ICD-10 Codes (continued)ICD-10Covered
    C57.00Malignant neoplasm of unspecified fallopian tube
    C57.01Malignant neoplasm of right fallopian tube
    C57.02Malignant neoplasm of left fallopian tube
    C57.10Malignant neoplasm of unspecified broad ligament
    C57.11Malignant neoplasm of right broad ligament
    C57.12Malignant neoplasm of left broad ligament
    C57.20Malignant neoplasm of unspecified round ligament
    C57.21Malignant neoplasm of right round ligament
    C57.22Malignant neoplasm of left round ligament
    C57.3Malignant neoplasm of parametrium
    1–10 of 32
    1/4
    Covered ICD-10 Codes (continued)ICD-10Covered
    C7A.098Malignant carcinoid tumors of other sites
    C7A.1Malignant poorly differentiated neuroendocrine tumors
    C7A.8Other malignant neuroendocrine tumors
    C7B.00Secondary carcinoid tumors unspecified site
    C7B.01Secondary carcinoid tumors of distant lymph nodes
    C7B.02Secondary carcinoid tumors of liver
    C7B.03Secondary carcinoid tumors of bone
    C7B.04Secondary carcinoid tumors of peritoneum
    C7B.09Secondary carcinoid tumors of other sites
    C7B.8Other secondary neuroendocrine tumors
    1–10 of 12
    1/2
    Covered ICD-10 Codes - Hodgkin lymphomaICD-10Covered
    C81.09Nodular lymphocyte predominant Hodgkin lymphoma, extranodal and solid organ sites
    C81.19Nodular sclerosis Hodgkin lymphoma, extranodal and solid organ sites
    C81.29Mixed cellularity Hodgkin lymphoma, extranodal and solid organ sites
    C81.39Lymphocyte depleted Hodgkin lymphoma, extranodal and solid organ sites
    C81.49Lymphocyte-rich Hodgkin lymphoma, extranodal and solid organ sites
    C81.79Other Hodgkin lymphoma, extranodal and solid organ sites
    C81.99Hodgkin lymphoma, unspecified, extranodal and solid organ sites
    Covered ICD-10 Codes - Non-Hodgkin lymphomas (partial)ICD-10Covered
    C82.09Follicular lymphoma grade I, extranodal and solid organ sites
    C82.19Follicular lymphoma grade II, extranodal and solid organ sites
    C82.29Follicular lymphoma grade III, unspecified, extranodal and solid organ sites
    C82.39Follicular lymphoma grade IIIa, extranodal and solid organ sites
    C82.49Follicular lymphoma grade IIIb, extranodal and solid organ sites
    C82.59Diffuse follicle center lymphoma, extranodal and solid organ sites
    C82.69Cutaneous follicle center lymphoma, extranodal and solid organ sites
    C82.89Other types of follicular lymphoma, extranodal and solid organ sites
    C82.99Follicular lymphoma, unspecified, extranodal and solid organ sites
    C83.00Small cell B-cell lymphoma, unspecified site
    1–10 of 11
    1/2
    Covered ICD-10 Diagnosis Codes (Appendix 1)ICD-10Covered
    C85.25Mediastinal (thymic) large B-cell lymphoma, lymph nodes of axilla and upper limb
    C85.26Mediastinal (thymic) large B-cell lymphoma, lymph nodes of inguinal region and lower limb
    C85.27Mediastinal (thymic) large B-cell lymphoma, intrapelvic lymph nodes
    C85.28Mediastinal (thymic) large B-cell lymphoma, spleen
    C85.29Mediastinal (thymic) large B-cell lymphoma, lymph nodes of multiple sites
    C85.80Other specified types of non-Hodgkin lymphoma, unspecified site
    C85.81Other specified types of non-Hodgkin lymphoma, lymph nodes of head, face, and neck
    C85.82Other specified types of non-Hodgkin lymphoma, intrathoracic lymph nodes
    C85.83Other specified types of non-Hodgkin lymphoma, intra-abdominal lymph nodes
    C85.84Other specified types of non-Hodgkin lymphoma, lymph nodes of axilla and upper limb
    1–10 of 36
    1/4
    Methotrexate level
    Methotrexate level thresholdContinue levoleucovorin until methotrexate level < 5 x 10^-8 M (0.05 micromolar)
    Monitoring frequencyMonitor serum creatinine and methotrexate levels at least every 24 hours during rescue therapy
    Dose escalation triggersIncrease levoleucovorin to 50 mg/m2 IV every 3 hours if 24-hour serum creatinine increases ≥50% from baseline, or if methotrexate level at 24 hours > 5 x 10^-6 M, or at 48 hours > 9 x 10^-7 M
    Standard rescue dosingAdminister 7.5 mg (≈5 mg/m2) IV every 6 hours for 10 doses starting 24 hours after methotrexate infusion (based on 12 g/m2 methotrexate over 4 hours)

    Provider Actions and Documentation

    Prior Authorization

    Obtain prior authorization — 90‑day initial approval; age ≥6

    Prior authorization is required for IV levoleucovorin. Initial prior authorization validity will be provided for 90 days and may be renewed every 90 days. The member must be at least 6 years of age to meet initial authorization requirements.

    Prior Authorization

    PA considered for indication and cost per NQTL checklist

    Prior authorization may be applied based on the clinical indication and the drug’s cost. Appendix A’s NQTL checklist identifies "Indication: Consider for PA" and "Cost of drug: Consider for PA," so providers should expect PA review when the indication relevance or cost is a concern.

    Note

    Follow applicable CMS NCDs/LCDs for Medicare Part B cases

    When Medicare Part B is relevant, follow applicable CMS guidance and any National Coverage Determinations (NCDs) or Local Coverage Determinations (LCDs). Coverage determinations for outpatient (Part B) drugs are governed by the Medicare Benefit Policy Manual and any applicable NCD/LCD/LCA.

    Initial Therapy Criteria

    Initial Therapy — Initial authorizations are for 90 days and require age and universal criteria

    Initial authorizations are for 90 days and require meeting the universal criteria and age requirement:

    Initial authorization prerequisites: Member is at least 6 years of age; member does not have pernicious anemia or vitamin B12 deficiency megaloblastic anemia; racemic d,l-leucovorin calcium is not obtainable in any dosage strength as confirmed by the FDA Drug Shortage website; for Khapzory only: member had an inadequate response to, or has a contraindication or intolerance to, Fusilev (levoleucovorin).

    Initial prior authorization valid for 90 days

    Renewal / Continuation Criteria

    Renewal Criteria

    Renewal may be approved when ALL of the following are met:

    Renewal requirements: Member continues to meet the universal and indication-specific relevant criteria (including required concomitant therapy where applicable); absence of unacceptable toxicity from levoleucovorin (examples: hypersensitivity reactions, hypercalcemia, severe gastrointestinal disorders such as stomatitis or severe diarrhea); member is responding to therapy.

    From Renewal Criteria

    Step Therapy Requirements

    StepRequired prior therapy / conditionCoverage note
    1Trial and inadequate response to, or contraindication/intolerance of, Fusilev (levoleucovorin)Required prior to coverage of Khapzory (Khapzory-only clause)

    Quantity Limits

    Fusilev (J0641) — Quantity Limit
    ProductFusilev (J0641)
    HCPCS descriptionJ0641 - Injection, levoleucovorin, not otherwise specified, 0.5 mg; 1 billable unit = 0.5 mg (Fusilev)
    Quantity limit2500 billable units every 28 days
    Khapzory (J0642) — Quantity Limit
    ProductKhapzory (J0642)
    HCPCS descriptionJ0642 - Injection, levoleucovorin (Khapzory), 0.5 mg; 1 billable unit = 0.5 mg
    Quantity limits3000 billable units every 28 days when used with fluorouracil; otherwise 2500 billable units every 28 days

    Site of Care and Administration

    Documentation Required

    Monitor serum creatinine and methotrexate levels during IV administration

    For IV administration in infusion center or hospital outpatient settings, follow dosing and monitoring guidance in the policy, including monitoring serum creatinine and methotrexate levels at least every 24 hours during rescue.

    Note

    Apply Medicare Part B rules and NCD/LCDs for outpatient administration/payment

    When administering in an outpatient infusion center under Medicare Part B, follow Medicare rules and any applicable NCDs/LCDs for coverage and payment; consult CMS guidance and local MACs as needed.

    Definitions

    Rescue therapy / combination therapy
    DefinitionRescue therapy: levoleucovorin used to mitigate methotrexate toxicity (e.g., after high-dose methotrexate) by administering scheduled IV doses until methotrexate levels fall below threshold
    Combination use with 5-FULevoleucovorin is used in combination with fluorouracil-based regimens to enhance 5-FU activity per indicated tumor types
    Monitoring contextWhen used as rescue therapy, monitor serum creatinine and methotrexate levels at least every 24 hours and continue levoleucovorin until methotrexate < 5 x 10^-8 M
    Medicare Part B Covered Diagnosis Codes
    Applicability in Appendix 2Medicare Part B Covered Diagnosis Codes: N/A in Appendix 2
    ImplicationNo specific Medicare Part B diagnosis codes are listed in this policy's Appendix 2; applicable NCDs/LCDs and CMS guidance must still be followed where relevant

    Background

    Levoleucovorin is used primarily as a rescue therapy following high‑dose methotrexate to reduce toxicity from impaired elimination or inadvertent overdosage of folic acid antagonists. It is also used in combination with fluorouracil‑based chemotherapy regimens to enhance fluorouracil activity for colorectal and other malignancies. Clinical use includes administration during high‑dose methotrexate chemotherapy or as part of methotrexate‑based regimens for specific tumor types; dosing and monitoring are performed in infusion or hospital outpatient settings.

    Policy Summary
    PayerViva Health
    PolicyLevoleucovorin (Fusilev; Khapzory) — Intravenous Coverage Criteria
    Policy CodePolicy IC-0183
    Change TypeNo material change
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization (initial approval 90 days; renew every 90 days) and confirm member is at least 6 years old.
    SourceLink
    On This Page
    Coverage CriteriaBilling and CodingProvider Actions and DocumentationInitial Therapy CriteriaRenewal / Continuation CriteriaStep Therapy RequirementsQuantity LimitsSite of Care and AdministrationDefinitionsBackground
    5-FU combination dosing
    When used with fluorouracil: levoleucovorin 100 mg/m2 IV (or 10 mg/m2 per alternate regimen) followed by 5-FU (370 mg/m2 or 425 mg/m2); repeat daily for 5 days and may be repeated at 28–35 day intervals
    Prior authorization consideration
    NQTL factors prompting PA considerationIndication relevance: 'Consider for PA' per Appendix A NQTL checklist
    Cost considerationCost of drug: 'Consider for PA' per Appendix A NQTL checklist
    Safety/efficacy conclusionSafety and efficacy: PA not a priority per Appendix A
    Potential misuse/abuse conclusionPotential for misuse/abuse: PA not a priority per Appendix A
    ApplicationPrior authorization may be applied when indication is relevant or when drug cost is a concern
    Medicare Part B Covered Diagnosis Codes
    Medicare Part B covered diagnosis codesN/A — policy notes Medicare Part B Covered Diagnosis Codes: N/A
    CMS guidance referenceMedicare outpatient (Part B) drug coverage follows Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 and applicable NCDs/LCDs
    NCD/LCD search linkUse CMS Coverage Database: https://www.cms.gov/medicare-coverage-database/search.aspx to locate applicable NCD/LCD/LCA documents
    Local coverage complianceCompliance with NCDs/LCDs (and LCAs for claims/payment) is required where applicable
    Step Therapy

    Document prior trial or intolerance to Fusilev before Khapzory

    For Khapzory (levoleucovorin), prior authorization requires documentation that the member had an inadequate response to, or a contraindication/intolerance of, Fusilev before Khapzory coverage is approved (Khapzory‑only prerequisite).

    Note
    Billing Rule

    Bill using HCPCS J0641 / J0642 and applicable NDC(s)

    Use the listed HCPCS and NDCs when submitting claims: bill levoleucovorin as J0641 (Fusilev) or J0642 (Khapzory), 1 billable unit = 0.5 mg, and include the applicable NDC for Fusilev or Khapzory (e.g., Fusilev 72893-0009-xx, 72893-0013-xx, 72893-0014-xx; Khapzory 72893-0004-xx, 72893-0006-xx).

    Documentation Required

    Refer to Appendix A for the NQTL factor checklist

    Appendix A contains the Non‑Quantitative Treatment Limitations (NQTL) factor checklist that documents the NQTL factors considered when designing and applying prior authorization for this drug/drug group.

    Documentation Required

    Submit supporting ICD‑10 diagnosis code from Appendix 1

    Include an appropriate ICD‑10 diagnosis code from Appendix 1 on the claim to support medical necessity for IV levoleucovorin; use the covered diagnosis code that corresponds to the member’s indication (see Appendix 1 list).

    Denial Risk

    Confirm FDA shortage before coverage when racemic product is required

    For indications that rely on racemic d,l‑leucovorin being unavailable, coverage requires confirmation that racemic d,l‑leucovorin calcium is not obtainable in any dosage strength as confirmed by the FDA Drug Shortage website (http://www.accessdata.fda.gov/scripts/drugshortages/default.cfm).

    Prior Authorization

    PA may be applied for NQTL‑driven utilization concerns

    Prior authorization may be applied when indication relevance or drug cost raises utilization management concerns; the policy notes that utilization management NQTLs may restrict benefits comparably across MH/SUD and M/S drugs.

    Note

    Medicare Part B coverage/payment triggers — follow CMS rules

    Medicare Part B coverage and payment for outpatient administration are governed by the Medicare Benefit Policy Manual and any applicable NCDs/LCDs/LCAs; providers must comply with these CMS rules where applicable.

    ReferenceSee CMS Medicare Coverage Database and Medicare Benefit Policy Manual for Part B coverage rules and any applicable NCD/LCD/LCA